NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,0.531416846277282,1.4517674218075731,18.416831004950268,1.26521490298,0.122016065451132,0.417960344683164,log2_fold_induction,2,0.366048196353396,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.80080096998253,1.80080096998253,-0.21580820329279,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,0.9143114527315671,1.372005598499508,0.3796878131247593,-0.4205733422270919,0.13328100901796647,0.957159671896628,log2_fold_induction,0.301029995663981,0.6664050450898323,,-0.11033905309455566,-0.49965369573402985,-1.1099164211768031,20,nuclear receptor
BSK_CASM3C_LDLR_down,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",NP_000518.1,LDLR,low density lipoprotein receptor,https://www.ncbi.nlm.nih.gov/gene/3949,"[57,57]",,Active,0.09289572054501485,1.1732035700617953,4,0.6020599913279624,0.024506084431499996,0.10219419199999999,log10_fold_induction,1,0.07918124604762482,"[""Borderline active"",""Less than 50% efficacy""]",0.6020599913279624,0.6020599913279624,-0.4093157669346721,20,misc protein
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.16532694449756485,1.220092803778447,4,0.6020599913279624,0.0451678604517,0.1763115,log10_fold_induction,0.602059991327962,0.1355035813551,"[""Less than 50% efficacy""]",0.6020599913279624,0.6020599913279624,-0.20223161381014196,20,cell cycle
BSK_LPS_TNFa_up,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_000585.2,TNF,tumor necrosis factor,https://www.ncbi.nlm.nih.gov/gene/7124,,,Active,0.21245878434503984,1.5603419079831127,1,0,0.04538722854225,0.192077845,log10_fold_induction,1.60205999132796,0.13616168562675,"[""Less than 50% efficacy""]",0,0,-4.180808351044755,20,cytokine
CCTE_Shafer_MEA_dev_AB_dn,"Data from the assay component CCTE_Shafer_MEA_dev_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_AB_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,80.6309589223151,4.133737179023638,2.744081614231211,0.438397023974641,6.50186142549743,83.4849113026296,percent_activity,1.30102999566398,19.5055842764923,,0.376389201520621,0.376389201520621,0.319116708015263,20,cell cycle
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,99.2865441073137,3.7501999662819148,2.067015259669535,0.315343682803298,8.825,100,percent_activity,1,26.475,,0.181150859348479,0.181150859348479,0.0238941848735943,20,neurodevelopment
CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.013225303753,2.6083758566561825,1.621550049127288,0.209930357711033,12.7810344827586,100,percent_activity,1,38.3431034482758,,0.153784777575745,0.153784777575745,-0.0496613691498226,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_rate_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_rate was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_rate_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,107.941573505395,1.473659549980883,2.4825664863383885,0.394900888290573,24.4157644839102,100,percent_activity,1,73.2472934517306,,0.619011936029801,0.619011936029801,-0.264063919640624,20,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.651647167168,1.9736539723011037,2.047013778069796,0.311120765827892,16.9992052946372,100,percent_activity,1,50.9976158839116,,0.31257018585704,0.31257018585704,0.191840449548314,20,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.098474916166,1.416250593969067,6.993043066663024,0.844666202851495,23.5595017205814,100,percent_activity,0.477121254719662,70.6785051617442,"[""Noisy data""]",0.892246907900501,0.892246907900501,0.725385730414181,20,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.011074507061,1.5470101662964972,3.4718255209052864,0.54055789127056,21.5493249895668,100,percent_activity,1,64.6479749687004,,0.573308981387312,0.573308981387312,0.421275702466591,20,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.012511952993,1.1857509868223093,1.954319042447456,0.290995463714374,28.3962127730534,100,percent_activity,0.477121254719662,85.1886383191602,"[""Borderline active""]",0.38237907263044,0.38237907263044,0.171715149870661,20,neurodevelopment
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,93.8790426288631,3.9288399986856932,1.918110497602026,0.282873622186338,7.96495001580351,94.8696930977121,percent_activity,1.30102999566398,23.8948500474105,,0.155131171228371,0.155131171228371,0.0216813917743799,20,cell cycle
CCTE_Shafer_MEA_dev_mutual_information_norm_dn,"Data from the assay component CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_mutual_information_norm_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.356046295728,1.4005965502597038,2.0463114224659487,0.310971728479949,24.1221133658926,100,percent_activity,-0.522878745280338,72.3663400976778,"[""Noisy data""]",0.360633327988941,0.360633327988941,0.191691414465184,20,neurodevelopment
CCTE_Shafer_MEA_dev_mutual_information_norm_up,"Data from the assay component CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_mutual_information_norm_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,149.800574860091,2.0700311036580668,0.11554852538828674,-0.937235592545897,24.1221133658926,135.89901278524,percent_activity,-0.522878745280338,72.3663400976778,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Noisy data""]",-0.940910142789376,-0.940910142789376,-1.05651590626476,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_duration_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.0071964717,1.3059139916281743,1.0354697689612704,0.0151374239779438,25.5267440053011,100,percent_activity,0.477121254719662,76.5802320159033,,0.0794375142168161,0.0794375142168161,-0.104142904248711,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,103.852985793935,1.326699260447682,0.9338230816353159,-0.0297353956622661,26.0930739643514,100,percent_activity,0.477121254719662,78.2792218930542,,0.263581510580658,0.263581510580658,-0.605827596314874,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_peak was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_peak_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.901676734314,3.722551437773316,1.9246286221366966,0.284346940121506,9.03517192629845,100,percent_activity,0.477121254719662,27.1055157788953,,0.229974928357631,0.229974928357631,0.165066626336595,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.261966630775,1.7199770723504155,2.021115675469065,0.305591170408057,23.1130923289574,100,percent_activity,1,69.3392769868722,,0.484557609693112,0.484557609693112,-0.891323520578756,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.03819603027,2.949491954265307,4.065065578750023,0.609067556143995,11.305698018671,100,percent_activity,1,33.917094056013,,0.572827212442111,0.572827212442111,0.489786706601795,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.359799845139,1.8585092821569085,2.0341484703605257,0.308382648441734,18.1794087728033,100,percent_activity,0,54.5382263184099,"[""Noisy data""]",0.316664524211621,0.316664524211621,0.18910233251077,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.663037409295,1.8640693743092571,0.168348573639739,-0.77379055888988,18.1794087728033,116.141116962576,percent_activity,0,54.5382263184099,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Noisy data""]",-0.758211503227935,-0.758211503227935,-1.0080832630792,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.890084243492,1.8128140694781127,1.9219471633643714,0.283741444219775,18.5512836905804,100,percent_activity,0.477121254719662,55.6538510717412,,0.294992542677432,0.294992542677432,0.164461130373555,20,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_spike_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.161007507182,2.378837417309337,1.9909016342850885,0.299049803099978,14.1751326048452,100,percent_activity,0.477121254719662,42.5253978145356,,0.281610670312811,0.281610670312811,0.179769487696711,20,neurodevelopment
LTEA_HepaRG_ABCB11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003733.2,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",https://www.ncbi.nlm.nih.gov/gene/8647,"[27,27]",,Active,0.588143567295642,1.0479121529633488,2.1220814515012383,0.326762049338482,0.187084246719363,0.637241213916667,log2_fold_induction,2,0.561252740158089,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.34177401927132,1.34177401927132,-0.407249093258988,20,transporter
LTEA_HepaRG_ABCB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000918.2,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",https://www.ncbi.nlm.nih.gov/gene/5243,,,Active,0.397574007216835,1.0479153921830668,3.7240576648798833,0.571016397160336,0.126465046759354,0.401397611,log2_fold_induction,1,0.379395140278062,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active""]",2.43514619359807,2.43514619359807,-0.777068677732407,20,transporter
LTEA_HepaRG_ACLY_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001087.2,ACLY,ATP citrate lyase,https://www.ncbi.nlm.nih.gov/gene/47,,,Active,0.787783889236363,2.2501890441801957,3.8361680437779175,0.583897623234545,0.116698919330631,0.95609796533333,log2_fold_induction,1.47712125471966,0.350096757991893,,0.571775661836216,0.571775661836216,0.464617306517432,20,lyase
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1543,"[57,57]",,Active,4.33019498422335,4.808225418141661,29.543720122324842,1.47046518044357,0.300193564683644,3.23838357833333,log2_fold_induction,2,0.900580694050932,,0.729103909463644,0.729103909463644,0.25226154612402,20,cyp
LTEA_HepaRG_CYP1A2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000752.2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",https://www.ncbi.nlm.nih.gov/gene/1544,"[131,131]",,Active,1.71239876632115,1.8034878626210014,10.332473946234884,1.01420431886343,0.316497604782422,1.95693212974999,log2_fold_induction,2,0.949492814347266,,1.05923396632869,1.05923396632869,0.561995345638562,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,1.42909352797711,1.895711341244467,0.6720060010527523,-0.172626848653825,0.251285361310856,1.5358551545,log2_fold_induction,0.477121254719662,0.753856083932568,,-0.1514842756089,-0.1514842756089,-0.594419222341431,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,0.622587997703961,1.1101553023056423,3.2104527529900873,0.506566282953128,0.186937207917646,0.705097962666667,log2_fold_induction,1,0.560811623752938,"[""Borderline active"",""Borderline active""]",0.626319755500732,0.626319755500732,0.387281837138595,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1571,,,Active,0.904949425781008,1.8895333034178823,3.8676534310047437,0.587447551309219,0.159642493756543,1.3283095255,log2_fold_induction,2,0.478927481269629,,0.60825681402959,0.60825681402959,0.196850635096411,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",https://www.ncbi.nlm.nih.gov/gene/1576,,,Active,1.7315827303298,1.4593043601585385,3.6089649287472882,0.55738266168668,0.395526977922934,1.76666012741667,log2_fold_induction,1.47712125471966,1.1865809337688,,0.656210097953404,0.656210097953404,0.27828973668184,20,cyp
LTEA_HepaRG_CYP3A7_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000756.3,CYP3A7,"cytochrome P450, family 3, subfamily A, polypeptide 7",https://www.ncbi.nlm.nih.gov/gene/1551,,,Active,2.27667585235654,2.93353009519801,4.341501384198909,0.637639943824632,0.258695812266514,2.15811231266667,log2_fold_induction,1.47712125471966,0.776087436799542,,0.444063799668614,0.444063799668614,-0.0074376941650488,20,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2,CYP4A11,"cytochrome P450, family 4, subfamily A, polypeptide 11",https://www.ncbi.nlm.nih.gov/gene/1579,,,Active,2.31761522150853,3.6257131214334795,26.452948069872846,1.42247407936295,0.213072127136213,1.17273021058334,log2_fold_induction,1.47712125471966,0.639216381408639,,0.831609111814671,0.831609111814671,0.0776150815434944,20,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2,CYP4A22,"cytochrome P450, family 4, subfamily A, polypeptide 22",https://www.ncbi.nlm.nih.gov/gene/284541,,,Active,1.16329693179997,1.4401853234293875,2.2499858154985932,0.352179780213537,0.269247045935707,1.17576623466666,log2_fold_induction,2,0.807741137807121,,0.793326089759987,0.793326089759987,-0.829084431902017,20,cyp
LTEA_HepaRG_FABP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001434.1,FABP1,"fatty acid binding protein 1, liver",https://www.ncbi.nlm.nih.gov/gene/2168,,,Active,1.20971280441501,2.5066880630557096,4.135431075722404,0.616520786935636,0.160864691309103,1.1362494415,log2_fold_induction,1.47712125471966,0.482594073927309,,0.529640834848633,0.529640834848633,0.150826007843012,20,transporter
LTEA_HepaRG_FASN_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004095.4,FASN,fatty acid synthase,https://www.ncbi.nlm.nih.gov/gene/2194,"[58,34,34,58]",,Active,0.62368662998306,1.6969416875398304,3.181427719752495,0.502622060758089,0.122511895873739,0.67093492,log2_fold_induction,1.47712125471966,0.367535687621217,,0.575335471861983,0.575335471861983,0.0601178916301855,20,lyase
LTEA_HepaRG_PDK4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002603.1,PDK4,"pyruvate dehydrogenase kinase, isozyme 4",https://www.ncbi.nlm.nih.gov/gene/5166,,,Active,1.14604031012885,2.374294734827204,33.53923273622527,1.52555312320045,0.160895541360588,0.85728313466667,log2_fold_induction,2,0.482686624081764,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.28676904053658,1.28676904053658,-0.124636012989022,20,kinase
LTEA_HepaRG_SLC10A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003040.1,SLC10A1,"solute carrier family 10 (sodium/bile acid cotransporter), member 1",https://www.ncbi.nlm.nih.gov/gene/6554,,,Active,0.452443861594363,1.4332074354147408,1.0654514639119785,0.0275336704412916,0.105228745542903,0.477952663666665,log2_fold_induction,1,0.315686236628709,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.264474032841962,0.264474032841962,-0.594806036997078,20,transporter
NVS_ENZ_hElastase,"Data from the assay component NVS_ENZ_hElastase was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hElastase, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_001963.1,ELANE,"elastase, neutrophil expressed",https://www.ncbi.nlm.nih.gov/gene/1991,,,Active,33.1535380821637,1.657676904108185,1.4503337276255173,0.161467946641703,1.98040145867003,35.6147021546261,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.480295652527392,-0.996361909088935,-1.51029028954423,20,protease
NVS_NR_hPPARg,"Data from the assay component NVS_NR_hPPARg was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARg, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,"[34,36,58,72,163,72,36,58,34,163]",,Active,30.8147794135348,1.2724600519251246,5.725104531190161,0.757783420602254,4.03611615245008,30.6611570247934,percent_activity,1.30102999566398,24.2166969147005,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",0.828370700462593,0.734170122615844,0.638502880076387,20,nuclear receptor
STM_H9_OrnCyssISnorm_ratio_dn,"Data from the assay component STM_H9_OrnCyssISnorm_ratio was analyzed at the assay endpoint STM_H9_OrnCyssISnorm_ratio_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",, , , ,,,Active,1.0612280913078471,2.7109376881754197,0.47142266115931974,-0.326589544892093,0.13048721062294136,0.753619437744544,log2_fold_induction,0,0.3914616318688241,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",-0.5346397952052098,-0.5346397952052098,-1.1777957528272767,20,metabolite
STM_H9_OrnithineISnorm_perc_dn,"Data from the assay component STM_H9_OrnithineISnorm_perc was analyzed at the assay endpoint STM_H9_OrnithineISnorm_perc_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",, , , ,,,Active,0.386927151264369,1.9155921109962963,0.21463544503179627,-0.668298556784806,0.0673294258980023,0.33267186388961,log2_fold_induction,0,0.201988277694007,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",-0.540638696835831,-0.540638696835831,-3.84910692139589,20,metabolite
TOX21_ARE_BLA_Agonist_ch2,"Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,34.5157682654737,1.0208164630853223,6.71391354229245,0.826975744367003,5.63532060098133,34.5619876999,percent_activity,1.30102999566398,33.811923605888,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.03717488091738,0.824761406879202,0.707695428339869,20,channel 2
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,70.5162687858153,2.9381021946485855,188.2783159594683,2.27480030513923,4.0001030208237,27.7075288677,percent_activity,1.95424250943932,24.0006181249422,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.41124177159798,0.207134232786403,-0.592670643464514,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,REV3L,"REV3 like, DNA directed polymerase zeta catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/5980,,,Active,28.873265974208,1.101948292023041,0.5772382626328929,-0.238644889117744,4.36700254498032,49.3646322205,percent_activity,0.903089986991944,26.2020152698819,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",0.297633790932603,-0.28222837700034,-0.754709399531148,20,cell cycle
TOX21_FXR_BLA_antagonist_ratio,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1,NR1H4,"nuclear receptor subfamily 1, group H, member 4",https://www.ncbi.nlm.nih.gov/gene/9971,"[27,61,27,61]",[479],Active,23.6711741171146,1.18355870585573,3.8481238518378587,0.585249041355422,2.78938673282934,20.4176570074,percent_activity,1.90308998699194,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",2.04333387091322,0.0660700688221336,-1.30461683171735,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2","THRA | THRB","thyroid hormone receptor, alpha , thyroid hormone receptor, beta","https://www.ncbi.nlm.nih.gov/gene/7067 , https://www.ncbi.nlm.nih.gov/gene/7068",,,Active,39.2989469220953,1.7515442190459642,284.6049871353265,2.45424250596041,3.73945711206963,50.7087189519,percent_activity,-2.52287874528034,22.4367426724178,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",2.867727303996,1.12598876170808,-0.726565292741438,20,nuclear receptor